Wall Street brokerages expect Thermo Fisher Scientific Inc. (NYSE:TMO) to report sales of $6.79 billion for the current fiscal quarter, according to Zacks Investment Research. Six analysts have made estimates for Thermo Fisher Scientific’s earnings, with the highest sales estimate coming in at $6.81 billion and the lowest estimate coming in at $6.78 billion. Thermo Fisher Scientific reported sales of $6.51 billion during the same quarter last year, which indicates a positive year over year growth rate of 4.3%. The firm is scheduled to report its next quarterly earnings report on Wednesday, January 29th.
According to Zacks, analysts expect that Thermo Fisher Scientific will report full-year sales of $25.50 billion for the current fiscal year, with estimates ranging from $25.43 billion to $25.52 billion. For the next financial year, analysts forecast that the business will post sales of $26.96 billion, with estimates ranging from $26.73 billion to $27.16 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Thermo Fisher Scientific.
Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $2.94 EPS for the quarter, beating the consensus estimate of $2.88 by $0.06. The business had revenue of $6.27 billion during the quarter, compared to analysts’ expectations of $6.19 billion. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.16%. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period in the previous year, the business posted $2.62 EPS.
NYSE TMO traded up $0.66 on Friday, reaching $317.09. 1,298,431 shares of the company’s stock traded hands, compared to its average volume of 1,520,949. The firm has a market cap of $128.37 billion, a price-to-earnings ratio of 28.52, a P/E/G ratio of 2.08 and a beta of 1.12. The stock has a 50 day moving average price of $304.57 and a 200-day moving average price of $289.84. Thermo Fisher Scientific has a fifty-two week low of $208.34 and a fifty-two week high of $321.60. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.23 and a current ratio of 1.80.
Thermo Fisher Scientific announced that its board has initiated a stock repurchase program on Friday, November 8th that permits the company to buyback $2.50 million in outstanding shares. This buyback authorization permits the medical research company to purchase shares of its stock through open market purchases. Shares buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Tuesday, December 17th will be given a $0.19 dividend. The ex-dividend date of this dividend is Monday, December 16th. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.24%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 6.83%.
In other news, CEO Marc N. Casper sold 47,729 shares of the company’s stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $295.88, for a total transaction of $14,122,056.52. Following the completion of the transaction, the chief executive officer now directly owns 328,960 shares of the company’s stock, valued at approximately $97,332,684.80. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 2,271 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $298.00, for a total value of $676,758.00. Following the transaction, the chief executive officer now directly owns 283,502 shares of the company’s stock, valued at $84,483,596. The disclosure for this sale can be found here. 0.45% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Karp Capital Management Corp raised its position in shares of Thermo Fisher Scientific by 0.7% in the third quarter. Karp Capital Management Corp now owns 4,980 shares of the medical research company’s stock valued at $1,451,000 after buying an additional 35 shares during the last quarter. Brandywine Oak Private Wealth LLC raised its holdings in Thermo Fisher Scientific by 2.0% in the 3rd quarter. Brandywine Oak Private Wealth LLC now owns 1,813 shares of the medical research company’s stock valued at $528,000 after acquiring an additional 36 shares during the last quarter. Signet Financial Management LLC lifted its stake in Thermo Fisher Scientific by 4.1% in the 3rd quarter. Signet Financial Management LLC now owns 937 shares of the medical research company’s stock worth $275,000 after purchasing an additional 37 shares in the last quarter. Landmark Bank lifted its stake in Thermo Fisher Scientific by 0.3% in the 3rd quarter. Landmark Bank now owns 13,623 shares of the medical research company’s stock worth $3,968,000 after purchasing an additional 40 shares in the last quarter. Finally, Arvest Bank Trust Division boosted its holdings in shares of Thermo Fisher Scientific by 2.8% during the 3rd quarter. Arvest Bank Trust Division now owns 1,454 shares of the medical research company’s stock worth $424,000 after purchasing an additional 40 shares during the last quarter. 88.35% of the stock is owned by institutional investors.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Further Reading: Reverse Stock Split
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.